MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 562611 | Name: RA-2
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RA-2 is a pan-negative-gating modulator of KCa2/3 channels. It acts by inhibiting EDH-type relaxation in coronary arteries.

Chemical Structure

RA-2
RA-2
CAS#1867107-62-7

Theoretical Analysis

MedKoo Cat#: 562611

Name: RA-2

CAS#: 1867107-62-7

Chemical Formula: C22H16F2O6

Exact Mass: 414.0915

Molecular Weight: 414.36

Elemental Analysis: C, 63.77; H, 3.89; F, 9.17; O, 23.17

Price and Availability

Size Price Availability Quantity
5mg USD 230.00 2 weeks
25mg USD 580.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
RA-2; RA 2; RA2;
IUPAC/Chemical Name
1,3-Phenylenebis(methylene) bis(3-fluoro-4-hydroxybenzoate)
InChi Key
XOZKRECPKXTNAK-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H16F2O6/c23-17-9-15(4-6-19(17)25)21(27)29-11-13-2-1-3-14(8-13)12-30-22(28)16-5-7-20(26)18(24)10-16/h1-10,25-26H,11-12H2
SMILES Code
O=C(OCC1=CC=CC(COC(C2=CC=C(O)C(F)=C2)=O)=C1)C3=CC=C(O)C(F)=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
RA-2 is a potent negative modulator of calcium-activated potassium channels KCa2.3 and KCa3.1 (IC50 values are 2 and 17 nM, respectively), which displays >55-fold selectively for KCa2 and KCa3.1 over other KCa, Kv and Kir channels.
In vitro activity:
To be determined
In vivo activity:
Blood pressure telemetry in mice showed that intraperitoneal application of RA-2 did not increase blood pressure or cause gross behavioral deficits. However, it did decrease heart rates by about 145 beats per minute. This study identified RA-2 as a new pharmacophore with nanomolar potency. RA-2 may be of use to generate structurally new types of negative-gating modulators that could help to define the role of KCa2/3 in the vasculature, central nervous system, and during inflammation in vivo. Reference: Mol Pharmacol. 2015 Feb;87(2):338-48. https://pubmed.ncbi.nlm.nih.gov/25468883/
Solvent mg/mL mM
Solubility
DMSO 41.4 100.00
Ethanol 41.4 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 414.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Oliván-Viguera A, Valero MS, Coleman N, Brown BM, Laría C, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Wulff H, Badorrey R, Köhler R. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Mol Pharmacol. 2015 Feb;87(2):338-48. doi: 10.1124/mol.114.095745. Epub 2014 Dec 2. PMID: 25468883; PMCID: PMC4293453. 2. Guzhova IV, Margulis BA, Kaminskaya EV. Antibody against p58 surface antigen of RA-2 rat rhabdomyosarcoma cells inhibits their metastatic activity. Int J Cancer. 1992 Dec 2;52(6):892-5. doi: 10.1002/ijc.2910520611. PMID: 1459731.
In vitro protocol:
To be determined
In vivo protocol:
1. Oliván-Viguera A, Valero MS, Coleman N, Brown BM, Laría C, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Wulff H, Badorrey R, Köhler R. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Mol Pharmacol. 2015 Feb;87(2):338-48. doi: 10.1124/mol.114.095745. Epub 2014 Dec 2. PMID: 25468883; PMCID: PMC4293453. 2. Guzhova IV, Margulis BA, Kaminskaya EV. Antibody against p58 surface antigen of RA-2 rat rhabdomyosarcoma cells inhibits their metastatic activity. Int J Cancer. 1992 Dec 2;52(6):892-5. doi: 10.1002/ijc.2910520611. PMID: 1459731.
1: Uttley L, Bermejo I, Ren S, Martyn-St James M, Wong R, Scott DL, Young A, Stevenson M. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. 2018 Mar 15. doi: 10.1007/s40273-018-0639-0. [Epub ahead of print] Review. PubMed PMID: 29546668. 2: Sato A, Lyamzina Y. Diversity of Concerns in Recovery after a Nuclear Accident: A Perspective from Fukushima. Int J Environ Res Public Health. 2018 Feb 16;15(2). pii: E350. doi: 10.3390/ijerph15020350. Review. PubMed PMID: 29462905; PubMed Central PMCID: PMC5858419. 3: Singh JA, Hossain A, Mudano AS, Tanjong Ghogomu E, Suarez-Almazor ME, Buchbinder R, Maxwell LJ, Tugwell P, Wells GA. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 May 8;5:CD012657. doi: 10.1002/14651858.CD012657. Review. PubMed PMID: 28481462. 4: Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K. Dosing down with biologic therapies: a systematic review and clinicians' perspective. Rheumatology (Oxford). 2017 Nov 1;56(11):1847-1856. doi: 10.1093/rheumatology/kew464. Review. Erratum in: Rheumatology (Oxford). 2018 Mar 1;57(3):589. PubMed PMID: 28339632; PubMed Central PMCID: PMC5850865. 5: Hirata S, Tanaka Y. Combination therapy for early rheumatoid arthritis: a treatment holiday perspective. Expert Rev Clin Pharmacol. 2015 Jan;8(1):115-22. doi: 10.1586/17512433.2015.984689. Epub 2014 Nov 25. Review. PubMed PMID: 25420554. 6: Siu S, Haraoui B, Bissonnette R, Bessette L, Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, Kraft J, Lynde C, Gulliver W, Keeling S, Dutz J, Pope JE. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. Arthritis Care Res (Hoboken). 2015 May;67(6):754-64. doi: 10.1002/acr.22519. Review. PubMed PMID: 25418272. 7: Cen H, Wang W, Leng RX, Wang TY, Pan HF, Fan YG, Wang B, Ye DQ. Association of IFIH1 rs1990760 polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Autoimmunity. 2013 Nov;46(7):455-62. doi: 10.3109/08916934.2013.796937. Epub 2013 Jun 4. Review. PubMed PMID: 23734776. 8: Naredo E, Wakefield RJ, Iagnocco A, Terslev L, Filippucci E, Gandjbakhch F, Aegerter P, Aydin S, Backhaus M, Balint PV, Bruyn GA, Collado P, Finzel S, Freeston JE, Gutierrez M, Joshua F, Jousse-Joulin S, Kane D, Keen HI, Moller I, Mandl P, Ohrndorf S, Pineda C, Schmidt WA, Szkudlarek M, Conaghan PG, D'Agostino MA. The OMERACT ultrasound task force--status and perspectives. J Rheumatol. 2011 Sep;38(9):2063-7. doi: 10.3899/jrheum.110425. PubMed PMID: 21885518. 9: Pincus T, Callahan LF, Sokka T. A Standard Protocol to Evaluate Rheumatoid Arthritis (SPERA) for efficient capture of essential data from a patient and a health professional in a uniform "scientific" format. Rheum Dis Clin North Am. 2009 Nov;35(4):843-50, xi. doi: 10.1016/j.rdc.2009.10.016. Review. PubMed PMID: 19962628. 10: Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009 Dec;20(6):685-91. doi: 10.1016/j.copbio.2009.10.011. Epub 2009 Nov 4. Review. PubMed PMID: 19896358. 11: Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007 Aug;28(4):369-78. Review. PubMed PMID: 17764055. 12: Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J Rheumatol. 2006 Nov;33(11):2124-31. Review. PubMed PMID: 17086602. 13: Straub RH, Cutolo M. Involvement of the hypothalamic--pituitary--adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum. 2001 Mar;44(3):493-507. Review. PubMed PMID: 11263762. 14: Binder TM, Rosenhek R, Frank H, Gwechenberger M, Maurer G, Baumgartner H. Congenital malformations of the right atrium and the coronary sinus: an analysis based on 103 cases reported in the literature and two additional cases. Chest. 2000 Jun;117(6):1740-8. Review. PubMed PMID: 10858411. 15: Yoshizumi K, Nagahata Y, Yamaguchi T, Kawakita N, Wada T, Yamamoto M, Saitoh Y. [A case report of allergic granulomatous angitis with the perforation of ileum]. Nihon Geka Gakkai Zasshi. 1994 Sep;95(9):704-8. Review. Japanese. PubMed PMID: 7838112. 16: Brauth SE, Heaton JT, Durand SE, Liang W, Hall WS. Functional anatomy of forebrain auditory pathways in the budgerigar (Melopsittacus undulatus). Brain Behav Evol. 1994;44(4-5):210-33. Review. PubMed PMID: 7842282. 17: Wattel E, Laï JL, Hebbar M, Preudhomme C, Grahek D, Morel P, Bauters F, Fenaux P. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features? Leuk Res. 1993 Nov;17(11):921-6. Review. PubMed PMID: 8231232. 18: Fried BJ, Boers M, Baker PR. A method for achieving consensus on rheumatoid arthritis outcome measures: the OMERACT conference process. J Rheumatol. 1993 Mar;20(3):548-51. Review. PubMed PMID: 8478870. 19: Tsuda H, Yokoyama M, Hashimoto H, Hirose S. [Plasmapheresis for patients with RA]. Nihon Rinsho. 1992 Mar;50(3):543-6. Review. Japanese. PubMed PMID: 1588745. 20: Heath CW Jr, Fortin PR. Epidemiologic studies of rheumatoid arthritis: future directions. J Rheumatol Suppl. 1992 Jan;32:74-7; discussion 77-9. Review. PubMed PMID: 1613736.